FR2858628B1 - Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines - Google Patents

Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines

Info

Publication number
FR2858628B1
FR2858628B1 FR0309612A FR0309612A FR2858628B1 FR 2858628 B1 FR2858628 B1 FR 2858628B1 FR 0309612 A FR0309612 A FR 0309612A FR 0309612 A FR0309612 A FR 0309612A FR 2858628 B1 FR2858628 B1 FR 2858628B1
Authority
FR
France
Prior art keywords
nucleic acid
protein expression
rna interference
acid complexes
inhibiting protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0309612A
Other languages
English (en)
Other versions
FR2858628A1 (fr
Inventor
Patrick Erbacher
Abdemaji Adib
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polyplus Transfection SA
Original Assignee
Polyplus Transfection SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyplus Transfection SA filed Critical Polyplus Transfection SA
Priority to FR0309612A priority Critical patent/FR2858628B1/fr
Priority to PCT/FR2004/002086 priority patent/WO2005014837A1/fr
Publication of FR2858628A1 publication Critical patent/FR2858628A1/fr
Application granted granted Critical
Publication of FR2858628B1 publication Critical patent/FR2858628B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
FR0309612A 2003-08-04 2003-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines Expired - Lifetime FR2858628B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0309612A FR2858628B1 (fr) 2003-08-04 2003-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines
PCT/FR2004/002086 WO2005014837A1 (fr) 2003-08-04 2004-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhiber l'expression de proteines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0309612A FR2858628B1 (fr) 2003-08-04 2003-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines

Publications (2)

Publication Number Publication Date
FR2858628A1 FR2858628A1 (fr) 2005-02-11
FR2858628B1 true FR2858628B1 (fr) 2008-01-04

Family

ID=34073010

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0309612A Expired - Lifetime FR2858628B1 (fr) 2003-08-04 2003-08-04 Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines

Country Status (2)

Country Link
FR (1) FR2858628B1 (fr)
WO (1) WO2005014837A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005277547B2 (en) 2004-08-16 2011-08-25 Immune Disease Institute, Inc. Method of delivering RNA interference and uses thereof
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
JP5407862B2 (ja) * 2006-10-04 2014-02-05 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィーク（セーエヌエールエス） ｓｉＲＮＡおよび脂質性４，５−二置換２−デオキシストレプタミン環アミノグリコシド誘導体を含む組成物ならびにその用途
FR2941152B1 (fr) 2009-01-20 2013-10-18 Centre Nat Rech Scient Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
WO2012075337A2 (fr) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Administration dirigée d'agents à une anatomie neuronale

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US6060456A (en) * 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
CA2300938A1 (fr) * 1997-08-20 1999-02-25 Somagenics, Inc. Produits therapeutiques antisens a proprietes de liaison ameliorees et leurs methodes d'utilisation
WO2001072280A2 (fr) * 2000-03-24 2001-10-04 Biosphere Medical Inc. Compositions et methodes pour therapie genique
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system

Also Published As

Publication number Publication date
FR2858628A1 (fr) 2005-02-11
WO2005014837A1 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
DE60126828D1 (de) "pyrazolverbindungen, die sich als proteinkinaseinhibitoren eignen"
WO2005007814A3 (fr) Mappage genomique d'elements d'adn fonctionnels et de proteines cellulaires
NO20020474D0 (no) Targeting av multimere kontrastmidler gjennom multilocus binding
ATE439376T1 (de) Gag-bindende proteine
NO20015828L (no) Fremgangsmåter for fremstilling av 5'-nukleinsyre- proteinkonjugater
ATE267246T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem rna-virus enthalten
DE60105696D1 (de) Eisenhaltige Proteinzusammensetzung
FR2858628B1 (fr) Nouveaux complexes d'acides nucleiques actifs pour l'arn interference et leur utilisation pour inhibiber l'expression de proteines
DE602004015504D1 (de) Von injektionspräparaten
FR2775295B1 (fr) Fragment d'adn specifique de streptococcus agalactiae et molecules d'acides nucleiques apparentees
BR9710919A (pt) Proteina purificada sr-p70
AU2003284127A8 (en) Nucleic acid supported protein complementation
NO20041763L (no) Regulert nukleinsyreekspresjonssystem
FR2857003B1 (fr) Nouveau catalyseur pour le vaporeformage de l'ethanol
FR2864083B1 (fr) Nouveaux derives d'acides phenyl-boroniques et leurs procedes de preparation.
DE60236511D1 (de) Biosynthetische gene zur herstellung von butenyl-spinosyn-haltigem insektizid
FR2862660B1 (fr) Systeme d'expression inductible de proteines recombinantes chez les cyanobacteries.
ATE368115T1 (de) Bakterielle insektizidproteine
EP1497305A4 (fr) Proteine 1 de liaison a l'adn sensible a l'insuline et methodes destinees a reguler des genes sensibles a l'insuline
EP1587928A4 (fr) Molecule d'acide nucleique humaine saa3, proteine, et procedes d'utilisation
AU1351501A (en) Gene sequences identified by protein motif database searching
AU2002361950A1 (en) Genes coding for dna replication proteins and for proteins related to pathogenesis
DE60014616D1 (de) Antikörper gegen plazentaprotein 13
ITMI20040046A1 (it) Disposizione di scala d'alcova
NO20020794D0 (no) Meg-1-protein

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20